P I Industries Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹42.6K Cr
PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY. - Domestic branded revenue is growing at about 5% with volume growth at 8%. - The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase. - Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally. - New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years. - Agrochemical markets are mixed currently, but visibility is expected to improve in the next 1-2 quarters. - CAPEX plans include building new multiproduct plants to support future growth with Rs. Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years. - Pharma business expected to breakeven and achieve critical mass (Rs.
From P I Industries Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹2,497
Market Cap
₹42.6K Cr
P/E Ratio
35.5
How does P I Industries Ltd rank in Fertilizers & Agrochemicals?
Compare P I Industries Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
P I Industries Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.6K Cr, net profit ₹200 Cr.
Full financials →📊 Revenue & Sales Performance
- →PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY.
- →Domestic branded revenue is growing at about 5% with volume growth at 8%.
- →The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase.
- →Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally.
- →New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years.
- →Agrochemical markets are mixed currently, but visibility is expected to improve in the next 1-2 quarters.
- →CAPEX plans include building new multiproduct plants to support future growth with Rs. 800-1,000 crore planned for next year.
📈 Profitability & Margins
- →Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years.
- →Pharma business expected to breakeven and achieve critical mass (Rs. 500-750 crore revenues) in about 2 years.
- →Biologicals segment is growing rapidly (25-30% growth expected next year), moving towards becoming a dominant player domestically and internationally.
- →AgChem exports growing steadily, new products showing 35-40% growth YoY, helping sustain overall growth amid macro uncertainties.
- →EBITDA margin improvement is structural due to superior product mix and cost efficiencies; pharma business currently in investment/build phase depressing near-term margins but expected to improve.
- →Overall company targeting sustained 20-25% CAGR over two decades through diversification and innovation.
- →Current small scale of pharma/biologicals means meaningful contributions expected in 2-3 years, reflecting long gestation business models with potential for significant positive earnings impact thereafter.
🏗️ Capital Expenditure Plans
- →PI Industries plans to invest in building two new multiproduct plants in the coming year to meet future business requirements.
- →The capital expenditure (CAPEX) guidance for the next year is estimated between Rs. 800 to 1,000 crore.
- →Pharma segment CAPEX includes investments in hardware, software, and regulatory compliance to build capabilities across the value chain; this investment phase will take a couple of years to generate significant value.
- →The company is aggressively investing in scaling the Plant Health Care technology platform globally over the next two or more years.
- →These capex initiatives are aimed at supporting growth in agrochemicals, pharma CDMO, biologicals, and specialty chemicals segments, positioning the company for long-term expansion across multiple verticals.
💰 Fundraising & Capital Structure
- →No explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
- →The company highlights a strong balance sheet with a healthy net cash balance of Rs. 42,091 million.
- →They emphasize having the capacity to scale up and accelerate investments in new initiatives over the next two years.
- →Investments are being made mainly from internal accruals for building differentiated capabilities in pharma, biologicals, and other verticals.
- →No announcements or indications of fresh capital raising via equity or debt were discussed for the near future.
- →The focus remains on organic scaling and measured capital allocation rather than external fundraising.
📋 Order Book & Pipeline
- →The order book remains approximately at the same level, around USD 1.4 billion (Page 10).
- →Growth is influenced not only by the order book but also by annual purchase orders and long-term agreements (Page 9).
- →The company is maintaining and sustaining current volumes, with overall industry conditions being in transition due to trade wars, tariffs, and other challenges (Page 9).
- →Clarity on growth visibility for FY26 or FY27 is expected in the next one or two quarters (Page 9).
Key Metrics
Frequently Asked Questions
What were P I Industries Ltd Q3 FY25 results?
PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY. - Domestic branded revenue is growing at about 5% with volume growth at 8%. - The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase. - Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally. - New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years. - Agrochemical markets are mixed currently, but visibility is expected to improve in the next 1-2 quarters. - CAPEX plans include building new multiproduct plants to support future growth with Rs. Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years. - Pharma business expected to breakeven and achieve critical mass (Rs.
What is P I Industries Ltd share price analysis?
P I Industries Ltd currently shows a neutral. The stock trades at a P/E of 35.5 with a market cap of ₹42,633 Cr. Investors should review the full earnings analysis for detailed insights.
Is P I Industries Ltd planning capital expenditure?
PI Industries plans to invest in building two new multiproduct plants in the coming year to meet future business requirements. - The capital expenditure (CAPEX) guidance for the next year is estimated between Rs.
Keep P I Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.